Equities

Regenxbio Inc

Regenxbio Inc

Actions
  • Price (EUR)10.70
  • Today's Change0.000 / 0.00%
  • Shares traded--
  • 1 Year change-31.85%
  • Beta--
Data delayed at least 15 minutes, as of Nov 12 2024 07:02 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments275365457
Total Receivables, Net252832
Total Inventory------
Prepaid expenses151419
Other current assets, total209.3510
Total current assets335416519
Property, plant & equipment, net193207192
Goodwill, net------
Intangibles, net------
Long term investments39201392
Note receivable - long term0.701.502.26
Other long term assets4.816.406.43
Total assets5748331,114
LIABILITIES
Accounts payable232711
Accrued expenses575367
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total515053
Total current liabilities130130130
Total long term debt000
Total debt000
Deferred income tax------
Minority interest------
Other liabilities, total132187219
Total liabilities262317350
SHAREHOLDERS EQUITY
Common stock0.000.000.00
Additional paid-in capital1,021973928
Retained earnings (accumulated deficit)(705)(442)(161)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(4.43)(15)(2.57)
Total equity312516764
Total liabilities & shareholders' equity5748331,114
Total common shares outstanding444343
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.